Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis
PURPOSE:The purpose of this study was to determine the effectiveness of topically applied besifloxacin (0.6%), gatifloxacin (0.3%), and moxifloxacin (0.5%) for the late treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) keratitis. METHODS:One hundred colony-forming units (C...
Gespeichert in:
| Veröffentlicht in: | Cornea 2009-10, Vol.28 (9), p.1055-1060 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1060 |
|---|---|
| container_issue | 9 |
| container_start_page | 1055 |
| container_title | Cornea |
| container_volume | 28 |
| creator | Sanders, Melissa E Norcross, Erin W Moore, Quincy C Shafiee, Afshin Marquart, Mary E |
| description | PURPOSE:The purpose of this study was to determine the effectiveness of topically applied besifloxacin (0.6%), gatifloxacin (0.3%), and moxifloxacin (0.5%) for the late treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) keratitis.
METHODS:One hundred colony-forming units (CFUs) of bacteria were injected intrastromally into rabbit corneas. Sixteen hours after infection, one topical drop of phosphate-buffered saline, besifloxacin, gatifloxacin, or moxifloxacin was applied to each eye every 15 minutes for 5 doses and then every 30 minutes for 14 doses. Eyes were examined before and after treatment by slit lamp biomicroscopy. Corneas were harvested from treated and untreated rabbits for the quantitation of bacteria. Minimal inhibitory concentrations (MICs) were determined in vitro for each fluoroquinolone.
RESULTS:None of the treatments had an effect on clinical severity (P > 0.05). Although there were no differences in clinical severity between any groups after treatment, the mean log10 CFU of MRSA recovered from besifloxacin-treated corneas (5.111 ± 0.251) was significantly lower than the CFU recovered from corneas treated with phosphate-buffered saline (7.006 ± 0.144), gatifloxacin (7.108 ± 0.346), and moxifloxacin (7.473 ± 0.144; P < 0.001). CFU recovered from gatifloxacin- and moxifloxacin-treated corneas were not significantly different from phosphate-buffered saline-treated corneas (P = 1.000). The MICs against the MRSA strain were 8 μg/mL for both gatifloxacin and moxifloxacin, whereas the MIC for besifloxacin was 1 μg/mL.
CONCLUSION:Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea 16 hours after infection. |
| doi_str_mv | 10.1097/ICO.0b013e31819e34cb |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734201165</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734201165</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355b-f029efaa55884aa659239a31f9ac99feba9e59da98e6cdd28006a70ca746711e3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gcjePG1NNrubzVFL_UCL4Md5mc1OaDRtapKl9t-7pQXBgzAwl-d9h3kIOWd0zKgUVw-T5zFtKOPIWcUk8lw1B2TICl6muZDVIRnSTIiUi5wOyEkIH5RSIcrsmAyYFFmeUT4kaqq1UaA2idPJDQajrfsGZZZJP5C8QNOYmMxci3ZLzDDOjTLWmmX60tMhwjImrxFW8411yinVhQQ6j_16RA_RRBNOyZEGG_Bsv0fk_Xb6NrlPn57vHibXT6niRdGkmmYSNUBRVFUOUBYy4xI40xKUlBobkFjIFmSFpWrbrKK0BEEViLwUjCEfkctd78q7rw5DrBcmKLQWlui6UAve_8xYWfRkviOVdyF41PXKmwX4Tc1ovbVb93brv3b72MX-QNcssP0N7XX2QLUD1s5G9OHTdmv09RzBxvn_3T-xR4p0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734201165</pqid></control><display><type>article</type><title>Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><creator>Sanders, Melissa E ; Norcross, Erin W ; Moore, Quincy C ; Shafiee, Afshin ; Marquart, Mary E</creator><creatorcontrib>Sanders, Melissa E ; Norcross, Erin W ; Moore, Quincy C ; Shafiee, Afshin ; Marquart, Mary E</creatorcontrib><description>PURPOSE:The purpose of this study was to determine the effectiveness of topically applied besifloxacin (0.6%), gatifloxacin (0.3%), and moxifloxacin (0.5%) for the late treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) keratitis.
METHODS:One hundred colony-forming units (CFUs) of bacteria were injected intrastromally into rabbit corneas. Sixteen hours after infection, one topical drop of phosphate-buffered saline, besifloxacin, gatifloxacin, or moxifloxacin was applied to each eye every 15 minutes for 5 doses and then every 30 minutes for 14 doses. Eyes were examined before and after treatment by slit lamp biomicroscopy. Corneas were harvested from treated and untreated rabbits for the quantitation of bacteria. Minimal inhibitory concentrations (MICs) were determined in vitro for each fluoroquinolone.
RESULTS:None of the treatments had an effect on clinical severity (P > 0.05). Although there were no differences in clinical severity between any groups after treatment, the mean log10 CFU of MRSA recovered from besifloxacin-treated corneas (5.111 ± 0.251) was significantly lower than the CFU recovered from corneas treated with phosphate-buffered saline (7.006 ± 0.144), gatifloxacin (7.108 ± 0.346), and moxifloxacin (7.473 ± 0.144; P < 0.001). CFU recovered from gatifloxacin- and moxifloxacin-treated corneas were not significantly different from phosphate-buffered saline-treated corneas (P = 1.000). The MICs against the MRSA strain were 8 μg/mL for both gatifloxacin and moxifloxacin, whereas the MIC for besifloxacin was 1 μg/mL.
CONCLUSION:Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea 16 hours after infection.</description><identifier>ISSN: 0277-3740</identifier><identifier>EISSN: 1536-4798</identifier><identifier>DOI: 10.1097/ICO.0b013e31819e34cb</identifier><identifier>PMID: 19724203</identifier><language>eng</language><publisher>United States: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><subject><![CDATA[Administration, Topical ; Animals ; Anti-Bacterial Agents - administration & dosage ; Aza Compounds - administration & dosage ; Azepines - administration & dosage ; Colony Count, Microbial ; Corneal Ulcer - drug therapy ; Corneal Ulcer - microbiology ; Disease Models, Animal ; Eye Infections, Bacterial - drug therapy ; Eye Infections, Bacterial - microbiology ; Female ; Fluoroquinolones - administration & dosage ; Male ; Methicillin-Resistant Staphylococcus aureus - drug effects ; Methicillin-Resistant Staphylococcus aureus - isolation & purification ; Microbial Sensitivity Tests ; Ophthalmic Solutions ; Quinolines - administration & dosage ; Rabbits ; Staphylococcal Infections - drug therapy ; Staphylococcal Infections - microbiology ; Treatment Outcome]]></subject><ispartof>Cornea, 2009-10, Vol.28 (9), p.1055-1060</ispartof><rights>Copyright © 2009 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c355b-f029efaa55884aa659239a31f9ac99feba9e59da98e6cdd28006a70ca746711e3</citedby><cites>FETCH-LOGICAL-c355b-f029efaa55884aa659239a31f9ac99feba9e59da98e6cdd28006a70ca746711e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19724203$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanders, Melissa E</creatorcontrib><creatorcontrib>Norcross, Erin W</creatorcontrib><creatorcontrib>Moore, Quincy C</creatorcontrib><creatorcontrib>Shafiee, Afshin</creatorcontrib><creatorcontrib>Marquart, Mary E</creatorcontrib><title>Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis</title><title>Cornea</title><addtitle>Cornea</addtitle><description>PURPOSE:The purpose of this study was to determine the effectiveness of topically applied besifloxacin (0.6%), gatifloxacin (0.3%), and moxifloxacin (0.5%) for the late treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) keratitis.
METHODS:One hundred colony-forming units (CFUs) of bacteria were injected intrastromally into rabbit corneas. Sixteen hours after infection, one topical drop of phosphate-buffered saline, besifloxacin, gatifloxacin, or moxifloxacin was applied to each eye every 15 minutes for 5 doses and then every 30 minutes for 14 doses. Eyes were examined before and after treatment by slit lamp biomicroscopy. Corneas were harvested from treated and untreated rabbits for the quantitation of bacteria. Minimal inhibitory concentrations (MICs) were determined in vitro for each fluoroquinolone.
RESULTS:None of the treatments had an effect on clinical severity (P > 0.05). Although there were no differences in clinical severity between any groups after treatment, the mean log10 CFU of MRSA recovered from besifloxacin-treated corneas (5.111 ± 0.251) was significantly lower than the CFU recovered from corneas treated with phosphate-buffered saline (7.006 ± 0.144), gatifloxacin (7.108 ± 0.346), and moxifloxacin (7.473 ± 0.144; P < 0.001). CFU recovered from gatifloxacin- and moxifloxacin-treated corneas were not significantly different from phosphate-buffered saline-treated corneas (P = 1.000). The MICs against the MRSA strain were 8 μg/mL for both gatifloxacin and moxifloxacin, whereas the MIC for besifloxacin was 1 μg/mL.
CONCLUSION:Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea 16 hours after infection.</description><subject>Administration, Topical</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Aza Compounds - administration & dosage</subject><subject>Azepines - administration & dosage</subject><subject>Colony Count, Microbial</subject><subject>Corneal Ulcer - drug therapy</subject><subject>Corneal Ulcer - microbiology</subject><subject>Disease Models, Animal</subject><subject>Eye Infections, Bacterial - drug therapy</subject><subject>Eye Infections, Bacterial - microbiology</subject><subject>Female</subject><subject>Fluoroquinolones - administration & dosage</subject><subject>Male</subject><subject>Methicillin-Resistant Staphylococcus aureus - drug effects</subject><subject>Methicillin-Resistant Staphylococcus aureus - isolation & purification</subject><subject>Microbial Sensitivity Tests</subject><subject>Ophthalmic Solutions</subject><subject>Quinolines - administration & dosage</subject><subject>Rabbits</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcal Infections - microbiology</subject><subject>Treatment Outcome</subject><issn>0277-3740</issn><issn>1536-4798</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotlb_gcjePG1NNrubzVFL_UCL4Md5mc1OaDRtapKl9t-7pQXBgzAwl-d9h3kIOWd0zKgUVw-T5zFtKOPIWcUk8lw1B2TICl6muZDVIRnSTIiUi5wOyEkIH5RSIcrsmAyYFFmeUT4kaqq1UaA2idPJDQajrfsGZZZJP5C8QNOYmMxci3ZLzDDOjTLWmmX60tMhwjImrxFW8411yinVhQQ6j_16RA_RRBNOyZEGG_Bsv0fk_Xb6NrlPn57vHibXT6niRdGkmmYSNUBRVFUOUBYy4xI40xKUlBobkFjIFmSFpWrbrKK0BEEViLwUjCEfkctd78q7rw5DrBcmKLQWlui6UAve_8xYWfRkviOVdyF41PXKmwX4Tc1ovbVb93brv3b72MX-QNcssP0N7XX2QLUD1s5G9OHTdmv09RzBxvn_3T-xR4p0</recordid><startdate>200910</startdate><enddate>200910</enddate><creator>Sanders, Melissa E</creator><creator>Norcross, Erin W</creator><creator>Moore, Quincy C</creator><creator>Shafiee, Afshin</creator><creator>Marquart, Mary E</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200910</creationdate><title>Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis</title><author>Sanders, Melissa E ; Norcross, Erin W ; Moore, Quincy C ; Shafiee, Afshin ; Marquart, Mary E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355b-f029efaa55884aa659239a31f9ac99feba9e59da98e6cdd28006a70ca746711e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Administration, Topical</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Aza Compounds - administration & dosage</topic><topic>Azepines - administration & dosage</topic><topic>Colony Count, Microbial</topic><topic>Corneal Ulcer - drug therapy</topic><topic>Corneal Ulcer - microbiology</topic><topic>Disease Models, Animal</topic><topic>Eye Infections, Bacterial - drug therapy</topic><topic>Eye Infections, Bacterial - microbiology</topic><topic>Female</topic><topic>Fluoroquinolones - administration & dosage</topic><topic>Male</topic><topic>Methicillin-Resistant Staphylococcus aureus - drug effects</topic><topic>Methicillin-Resistant Staphylococcus aureus - isolation & purification</topic><topic>Microbial Sensitivity Tests</topic><topic>Ophthalmic Solutions</topic><topic>Quinolines - administration & dosage</topic><topic>Rabbits</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcal Infections - microbiology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanders, Melissa E</creatorcontrib><creatorcontrib>Norcross, Erin W</creatorcontrib><creatorcontrib>Moore, Quincy C</creatorcontrib><creatorcontrib>Shafiee, Afshin</creatorcontrib><creatorcontrib>Marquart, Mary E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cornea</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanders, Melissa E</au><au>Norcross, Erin W</au><au>Moore, Quincy C</au><au>Shafiee, Afshin</au><au>Marquart, Mary E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis</atitle><jtitle>Cornea</jtitle><addtitle>Cornea</addtitle><date>2009-10</date><risdate>2009</risdate><volume>28</volume><issue>9</issue><spage>1055</spage><epage>1060</epage><pages>1055-1060</pages><issn>0277-3740</issn><eissn>1536-4798</eissn><abstract>PURPOSE:The purpose of this study was to determine the effectiveness of topically applied besifloxacin (0.6%), gatifloxacin (0.3%), and moxifloxacin (0.5%) for the late treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) keratitis.
METHODS:One hundred colony-forming units (CFUs) of bacteria were injected intrastromally into rabbit corneas. Sixteen hours after infection, one topical drop of phosphate-buffered saline, besifloxacin, gatifloxacin, or moxifloxacin was applied to each eye every 15 minutes for 5 doses and then every 30 minutes for 14 doses. Eyes were examined before and after treatment by slit lamp biomicroscopy. Corneas were harvested from treated and untreated rabbits for the quantitation of bacteria. Minimal inhibitory concentrations (MICs) were determined in vitro for each fluoroquinolone.
RESULTS:None of the treatments had an effect on clinical severity (P > 0.05). Although there were no differences in clinical severity between any groups after treatment, the mean log10 CFU of MRSA recovered from besifloxacin-treated corneas (5.111 ± 0.251) was significantly lower than the CFU recovered from corneas treated with phosphate-buffered saline (7.006 ± 0.144), gatifloxacin (7.108 ± 0.346), and moxifloxacin (7.473 ± 0.144; P < 0.001). CFU recovered from gatifloxacin- and moxifloxacin-treated corneas were not significantly different from phosphate-buffered saline-treated corneas (P = 1.000). The MICs against the MRSA strain were 8 μg/mL for both gatifloxacin and moxifloxacin, whereas the MIC for besifloxacin was 1 μg/mL.
CONCLUSION:Besifloxacin had an 8-fold lower MIC for MRSA than gatifloxacin and moxifloxacin and was significantly more effective than gatifloxacin and moxifloxacin in reducing the number of MRSA in the rabbit cornea 16 hours after infection.</abstract><cop>United States</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>19724203</pmid><doi>10.1097/ICO.0b013e31819e34cb</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3740 |
| ispartof | Cornea, 2009-10, Vol.28 (9), p.1055-1060 |
| issn | 0277-3740 1536-4798 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734201165 |
| source | MEDLINE; Journals@Ovid Ovid Autoload |
| subjects | Administration, Topical Animals Anti-Bacterial Agents - administration & dosage Aza Compounds - administration & dosage Azepines - administration & dosage Colony Count, Microbial Corneal Ulcer - drug therapy Corneal Ulcer - microbiology Disease Models, Animal Eye Infections, Bacterial - drug therapy Eye Infections, Bacterial - microbiology Female Fluoroquinolones - administration & dosage Male Methicillin-Resistant Staphylococcus aureus - drug effects Methicillin-Resistant Staphylococcus aureus - isolation & purification Microbial Sensitivity Tests Ophthalmic Solutions Quinolines - administration & dosage Rabbits Staphylococcal Infections - drug therapy Staphylococcal Infections - microbiology Treatment Outcome |
| title | Efficacy of Besifloxacin in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Keratitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T07%3A11%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Besifloxacin%20in%20a%20Rabbit%20Model%20of%20Methicillin-Resistant%20Staphylococcus%20aureus%20Keratitis&rft.jtitle=Cornea&rft.au=Sanders,%20Melissa%20E&rft.date=2009-10&rft.volume=28&rft.issue=9&rft.spage=1055&rft.epage=1060&rft.pages=1055-1060&rft.issn=0277-3740&rft.eissn=1536-4798&rft_id=info:doi/10.1097/ICO.0b013e31819e34cb&rft_dat=%3Cproquest_cross%3E734201165%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734201165&rft_id=info:pmid/19724203&rfr_iscdi=true |